drugset
drugset / Trial / NCT01743157

Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma

NCT01743157 ↗

Phase 1/2 Completed 24 enrolled California Pacific Medical Center Research Institute
NaSingle-groupOpen-labelTreatment

Summary

A phase I-II study of treatment of metastatic melanoma using induction therapy with Biochemotherapy plus Bevacizumab followed by consolidation therapy with Ipilimumab (BBI).

Timeline

Start
2010-12
Primary completion
2013-05
Completion
2013-05

Publications

  • Results 3. Minor DR, Wang W, Kashani-Sabet: Concurrent bevacizumab (BEV) with biochemotherapy (BIO) followed by ipilimumab for advanced melanoma: a phase I-II trial. J Clin Onc 2013 (suppl; abstr e200001)

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 7.5 mg/kg —
Subject Bevacizumab Monoclonal antibody 15 mg/kg —
Subject Cisplatin Other / unclassified 20 mg/m2 —
Subject Ipilimumab Monoclonal antibody 3 mg/kg —
Subject Temozolamide Unknown 150 mg/m2 —
Subject Vinblastine Small molecule 1.2 mg/m2 —
Subject aldesleukin Protein / enzyme biologic 9 iu —
Subject interferon alfa-2b Protein / enzyme biologic 5 mg/m2 —

Indications

metastatic melanoma